Arix Bioscience (ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through a combination of an expert investment team and portfolio diversification, sourced via its extensive network and partners. The company has announced a restructuring of its Board and executive team recently, which has resulted in a significant and sustainable reduction in its operating overhead, and greatly extended its cash runway.
Download the full report